drugset / Trial / NCT06765902
Immunotherapy Before and After Surgery
NaSingle-groupOpen-labelTreatment
Summary
This Phase 2 clinical trial is testing a new immunotherapy combination (N-803, ETBX-071, M-CENK) for men with high-risk prostate cancer before and after prostate surgery. The goal is to see if this treatment improves cancer outcomes and is safe.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2031-01-31
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ETBX-071 | Vaccine | — | Subcutaneous |
| Subject | M-CENK | Cell therapy | — | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | — | Subcutaneous |